List view / Grid view
Scientists have created a tiny, bioengineered 3D model that mimics the biology of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, a pair of rare, devastating neuromuscular diseases.
Scientists have successfully created viable organoids from tumour samples from five patients with a rare bone cancer called a chordoma, which has few therapeutic options.
The ImageXpress Confocal HT.ai High-Content Imaging System combines premium hardware technology with a self-learning software analysis workflow for increased signal and ultra-fast 3D organoid screening.
Read about hydrogels that provide defined and tuneable material properties that allow the controlled inclusion of biochemical cues.
Researchers have been using brain organoids to understand how a mutated gene affects the brain at its very early stage of development.
Scientists have opened a path towards triple-negative breast cancer treatment, by creating organoids from tumour samples.
A new study modelled chlamydia and HPV co-infection in patient-derived ectocervix organoids to reveal distinct cellular reprogramming.
Researchers have successfully generated organoids in suspension, offering the possibility of larger-scale experiments to study human development and disease.
Researchers have identified potential age-related macular degeneration drugs using a novel stem-cell based research tool.
Researchers have made a respiratory model of COVID-19, made from patient-derived stem cells, to understand how the virus affects respiration and which could be used to test possible drugs.
Scientists have developed a multi-organoid system from stem cells that can replicate the liver-islet axis in type 2 diabetes.
Learn about the high-content analysis system that provides high-quality three-dimensional imaging for enhanced live cell analysis.
Scientists identified three prototypical RNA-expression states and revealed differences in their susceptibility to a variety of cancer drugs.
Scientists develop organoid models of neuroendocrine prostate cancer to study EZH2 inhibitors and reveal a potential new target.
The European Medicines Agency is promoting three principles – replace, reduce and refine – to reduce animal testing in medicine development.
